NIH Conference
1 October 1971

Sulfonylureas: Effects in Vivo and in Vitro

Publication: Annals of Internal Medicine
Volume 75, Number 4

Abstract

To evaluate the effects of therapy on the vascular complications of adult diabetes, the University Group Diabetes Program (UGDP) carried out a prospective double-blind study in 12 centers of 823 newly diagnosed adult-type diabetics, who were randomly assigned to different treatment groups. Over a period of 8 years the overall incidence of nonfatal complications were the same for all groups, irrespective of the therapy—oral placebo, oral sulfonylureas, a small fixed dose of insulin, or a variable dose of insulin sufficient to normalize the blood glucose. Only the variable-dose insulin group maintained nearly normal blood glucose concentrations. In contrast to this, the sulfonylurea-treated group had a significantly increased incidence of fatal cardiovascular events. In vitro, sulfonylureas inhibited the important regulatory enzyme, cyclic AMP phosphodiesterase, in the pancreatic beta cell and in all other tissues tested, including the heart and platelets. In addition to inhibiting phosphodiesterase, sulfonylureas affected other processes in the platelet and in heart muscle. These studies confirm, in vitro, the direct multiple effects of sulfonylureas in many tissue sites outside of the beta cell.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
JOSLIN EROOT H, and WHITE P: The Treatment of Diabetes Mellitus, 10th ed. Philadelphia, Lea & Febiger, 1959
2.
RICKETTS H: The probem of degenerative vascular disease in diabetes. Am J Med 19:933-945, 1955
3.
KNOWLES H (quoted by RICKETTS HT): In On the Nature and Treatment of Diabetes, edited by LEIBEL BS, WRENSHALL GA. New York, Excerpta Medica Foundation, 1965, p. 595
4.
ROOT HPOTE W, and FREHNER H: Triopathy of diabetes: sequence of neuropathy, retinopathy and nephropathy in one hundred fifty-five patients. Arch Intern Med 94:931-941, 1954
5.
: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods and baseline results. Diabetes 19(suppl 2) :747-783, 1970
6.
: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19(suppl 2):789-830, 1970
7.
BUTTERFIELD W and WESTERING V (editors) : Tolbutamide— After 10 years. International Congress Series, vol. 149. New York, Excerpta Medica Foundation, 1967, p. 328
8.
KNATTERUD GMEINERT C, and KLIMT C: The University Group Diabetes Program: a study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. IV. A preliminary report on phenformin results. JAMA 217:777-784, 1971
9.
BALODIMOS MCAMERINI-DAVALOS R, and MARBLE A: Nine years' experience with tolbutamide in the treatment of diabetes. Metabolism 15:957-970, 1966
10.
DUNCAN L and BAIRD J: Compounds administered orally in the treatment of diabetes mellitus. Pharmacol Rev 12: 91-158, 1960
11.
CORNFELD J: Further statistical analysis of the mortality findings of the University Group Diabetes Program. JAMA 217: in press, 1971
12.
Med Lett Drugs Ther 12:97, 1970
13.
SUTHERLAND EROBISON G, and BUTCHER R: Some aspects of the biological role of adenosine 3′,5′-monophosphate (cyclic AMP). Circulation 37:279-306, 1968
14.
BUTCHER R: The role of cyclic AMP in hormone actions. N Engl J Med 279:1378-1384, 1968
15.
SUTHERLAND E and ROBISON G: The role of cyclic AMP in the control of carbohydrate metabolism. Diabetes 18:797-819, 1969
16.
PASTAN I and PERLMAN R: Cyclic AMP. Nature New Biol (London) 229:5-7, 1971
17.
LEFKOWITZ RROTH J, and PRICER W: ACTH receptors in the adrenal: specific binding of ACTH-125I and its relation to adenyl cyclase. Proc Natl Acad Sci USA 65:745-752, 1970
18.
BROOKER G and FICHMAN M: Chlorpropamide and tolbutamide inhibition of adenosine 3′5′-cyclic monophosphate phosphodiesterase. Biochem Biophys Res Commun 42:824-828, 1971
19.
MALAISSE WMALAISSE-LAGAE F, and MAYHEW D: A possible role for the adenylcyclase system in insulin secretion. J Clin Invest 46:1724-1734, 1967
20.
TURTLE J and KIPNIS D: An adrenergic receptor mechanism for the control of cyclic 3′5′-adenosine monophosphate in tissues. Biochem Biophys Res Commun 28:797-802, 1967
21.
SAMOLS EMARRI G, and MARKS V: Interrelationship of glucagon, insulin and glucose; the insulinogenic effect of glucagon. Diabetes 15:855-866, 1966
22.
ENSINCK JSTOLL R, and GALE C: Effect of aminophylline on the secretion of insulin, glucagon, luteinizing hormone and growth hormone in humans. J Clin Endocrinol Metab 31:153-161, 1970
23.
GRASSO SMESSINA A, and SAPORITO N: Effect of theophylline, glucagon, and theophylline plus glucagon on insulin secretion in the premature infant. Diabetes 19:837-841, 1970
24.
CERASI E and LUFT R: Effect of an adenosine 3′5′-monophosphate inhibitor (aminophylline) on the insulin response to glucose infusion in prediabetic and diabetic subjects. Hormone Metabol Res 1:162-168, 1969
25.
SODOYEZ JSODOYEZ-GOFFAUX F, and LEFEBVRE P: A transplantable insuloma of the Syrian hamster Mesocricetus auratus auratus. Review of its properties and of its effect on the host. Acta Diabetol Lat 5(suppl 1):86-104, 1968
26.
KRISHNA GWEISS B, and BRODIE B: A simple sensitive method for the assay of adenyl cyclase. J Pharmacol Exp Ther 163: 379-385, 1968
27.
HONDA F and HITOMI I: Inhibition of cyclic 3′,5′-nucleotide phosphodiesterase by phenothiazine and reserpine derivatives. Biochim Biophys Acta 161:267-269, 1968
28.
MOORE P: Effects of diazoxide and benzothiadiazine diuretics upon phosphodiesterase. Ann NY Acad Sci 150:256-260, 1968
29.
TRINER LVULLIEMOZ Y, and SCHWARTZ I: Cyclic phosphodiesterase activity and the action of papaverine, Biochem Biophys Res Commun 40:64-69, 1970
30.
MANDEL L and KUEHL F: Lipolytic action of 3,3′,5′, triiodo-L-thyronine, a cyclic AMP phosphodiesterase inhibitor. Biochem Biophys Res Commun 28:13-18, 1967
31.
WOLFE S and SHULMAN N: Inhibition of platelet energy production and release reaction by PGE1, theophylline and cAMP. Biochem Biophys Res Commun 41:125-134, 1970
32.
GAARDER AJONSEN J, and LALAND S: Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 192:531-532, 1961
33.
WOLFE S and SHULMAN N: Adenyl cyclase activity in human platelets. Biochem Biophys Res Commun 35:265-272, 1969
34.
ZIEVE P and GREENOUGH W: Adenyl cyclase in human platelets: activity and responsiveness. Ibid., pp. 462-466
35.
ARDLIE NGLENN G, and SCHULTZ B: Inhibition and reversal of platelet aggregation by methyl xanthines. Thromb Diath Haemorr 18:670-673, 1967
36.
MARQUIS NVIGDAHL R, and TAVORIMINA P: Platelet aggregation. I. Regulation by cyclic AMP and prostaglandin E1. Biochem Biophys Res Commun 36:965-972, 1969
37.
SALZMAN E and NERI L: Cyclic 3′,5′-adenosine monophosphate in human blood platelets. Nature 224:609-610, 1969
38.
SCOTT R: Effects of prostaglandin, epinephrine and NaF on human leucocyte, platelet and liver adenyl cyclase. Blood 35:514-516, 1970
39.
SALZMAN E and LEVINE L: Cyclic 3′,5′-adenosine monophosphate in human blood platelets. II. Effect of N6-2′-0-dibutyryl cyclic 3′,5′-adenosine monophosphate on platelet function. J Clin Invest 50:131-141, 1971
40.
MILLS D and SMITH J: The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3′,5′-cyclic monophosphate in platelets. Biochem J 121:185-196, 1971
41.
STEINER AKIPNIS D, and UTIGER R: Radioimmunoassay for the measurement of adenosine 3′,5′-cyclic phosphate. Proc Natl Acad Sci USA 64:367-373, 1969
42.
MURAD FCHI Y, and RALL T: Adenyl cyclase. III. The effect of catecholamines and choline esters on the formation of adenosine 3′,5′-phosphate by preparations from cardiac muscle and liver. J Biol Chem 237:1233-1238, 1962
43.
NAMM D and MAYER S: Effects of epinephrine on cardiac cyclic 3′,5′-AMP, Phosphorylase kinase and Phosphorylase. Mol Pharmacol 4:61, 1968
44.
BUTCHER R and SUTHERLAND E: Adenosine 3′,5′-phosphate in biological materials. J Biol Chem 237:1244-1250, 1962
45.
MARCUS MSKELTON C, and KARCH F: Potentiation of the inotropic effects of norepinephrine, glucagon and dibutyryl cyclic AMP by theophylline (abstract). Clin Res 19:327, 1971
46.
STETTEN D: The hypoglycemic sulfonylurea drugs—an interim evaluation. Ann Intern Med 46:1005-1008, 1957
47.
CHU PCONWAY M, and KROUSE H: The pattern of response of plasma insulin and glucose to meals and fasting during chlorpropamide therapy. Ann Intern Med 68:757-769, 1968
48.
SEGAL SFRAWLEY T, and FOLEY J: A comparison of the effects of tolbutamide and insulin on infused pentoses. A study in man. Diabetes 6:422-425, 1957
49.
WOLFF F: The mode of action of the sulfonamide derivatives in diabetes mellitus. Acta Diabetol Lat In press, 1971
50.
BROWN J and SOLOMON D: Effects of tolbutamide and carbutamide on thyroid function. Metabolism 5:813-819, 1956
51.
SEEGERS WMCGAVACK T, and HAAR H: Influence of arylsulfonylureas on thyroid function in older diabetic men and women. J Am Geriatr Soc 5:739-746, 1957
52.
SAMS W: Photosensitizing therapeutic agents. JAMA 174:2043-2048, 1960
53.
WRIGHT H: Corneal and lenticular opacities in the eyes of rats following long-term administration of sulfonylurea derivatives. A preliminary report. Diabetes 12:550-554, 1963
54.
FEARNLEY GCHAKRABARTI R, and VINCENT C: Effect of the sulfonylureas on fibrinolysis. Lancet 2:622-625, 1960
55.
BROD R: Blood dyscrasias associated with tolbutamide therapy. JAMA 171:296-297, 1959
56.
MOHNIKE G and BIBERGIL H: Effect of BZ55 and D-860 on blood glucose and serum phosphorus, potassium and sodium levels in dogs. Deutch Med Wochenschr 8:900-902, 1956
57.
FINE D and SHEDROVILZKY H: Hyponatremia due to chlorpropamide. A syndrome resembling inappropriate secretion of antidiuretic hormone. Ann Intern Med 72:83-87, 1970
58.
BERNDT WMILLER M, and KETTYLE W: Potentiation of the antidiuretic effect of vasopressin by chlorpropamide. Endocrinology 86:1028-1032, 1970
59.
ASHMORE JCAHILL G, and HASTINGS A: Inhibition of glucose 6-phosphatase by hypoglycemia sulfonylureas. Metabolism 5:774-777, 1956
60.
BORSTEIN J: Inhibition of alanine transaminase by the hypoglycaemic sulfonylurea derivatives. Nature 179:534-535, 1957
61.
BLOODWORTH J: Morphologic changes associated with sulfonylurea therapy. Metabolism 12:287, 1963
62.
PALMER RLASSETER K, and MCCARTHY J: Tolbutamide: an inotropic effect on rabbit atria. Lancet 1:604, 1967
63.
KHACHADURIAN A and BADEER H: Effect of tolbutamide on glucose utilization by denervated heart-lung preparation. Metabolism 9:890-896, 1960
64.
WOLFF F and GRANT A: Effect of tolbutamide on blood pressure. N Engl J Med 284:915-916, 1971
65.
MOSOVICK A and ETCHEPAREBORDA J: The role of oral antidiabetics as activators in epilepsy. Prensa Med Argent 50:2050-2060, 1963
66.
JADZINSKY MPOGORELSKY C, and DE PAULA A: Action of hypoglycemic drugs on the stomach. Sem Med (B Air) 122:439-443, 1963
67.
LEVEY GPALMER R, and LASSETER K: Effect of tolbutamide on adenyl cyclase in rabbit and human heart and contractility of isolated rabbit atria. J Clin Endocrinol In press, 1971
68.
MAROKO PKJEKSHUS J, and SOBEL B: Factors influencing infarct size following experiment coronary artery occlusion. Circulation 43:67-82, 1971
69.
Leading Article: Alcohol sensitivity to sulphonylureas. Br Med J 2:586-587, 1964
70.
HARTSHORN E: Drug interaction. Drug Intelligence 2:174, 1968

Information & Authors

Information

Published In

cover image Annals of Internal Medicine
Annals of Internal Medicine
Volume 75Number 41 October 1971
Pages: 607 - 621

History

Published in issue: 1 October 1971
Published online: 1 December 2008

Keywords

Authors

Affiliations

JESSE ROTH, M.D.
Baltimore and Bethesda, Maryland
THADDEUS E. PROUT, M.D.
Baltimore and Bethesda, Maryland
IRA D. GOLDFINE, M.D.
Baltimore and Bethesda, Maryland
SIDNEY M. WOLFE, M.D.
Baltimore and Bethesda, Maryland
JOSEPH MUENZER, B.S.
Baltimore and Bethesda, Maryland
LEONARD E. GRAUER, M.D.
Baltimore and Bethesda, Maryland
MELVIN L. MARCUS, M.D.
Baltimore and Bethesda, Maryland
*Chief, Diabetes Section, National Institute of Arthritis and Metabolic Diseases.
▸An edited transcription of a Combined Clinical Staff Conference at the Clinical Center, Bethesda, Md., by the National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, U.S. Department of Health, Education, and Welfare.

Metrics & Citations

Metrics

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
JESSE ROTH, THADDEUS E. PROUT, IRA D. GOLDFINE, et al. Sulfonylureas: Effects in Vivo and in Vitro. Ann Intern Med.1971;75:607-621. doi:10.7326/0003-4819-75-4-607

View More

Get Access

Login Options:
Purchase

You will be redirected to acponline.org to sign-in to Annals to complete your purchase.

Create your Free Account

You will be redirected to acponline.org to create an account that will provide access to Annals.

View options

PDF/ePub

View PDF/ePub

Related in ACP Journals

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media